Loading clinical trials...
Loading clinical trials...
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06252616 IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY
Conditions
Interventions
PF-06252616
Placebo
Locations
66
United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
Ronald Reagan UCLA Pharmacy
Los Angeles, California, United States
UCLA (David Geffen School of Medicine)
Los Angeles, California, United States
University of California, Davis Medical Center
Sacramento, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Shriners Hospitals for Children - Tampa
Tampa, Florida, United States
Start Date
November 24, 2014
Primary Completion Date
April 30, 2018
Completion Date
November 23, 2018
Last Updated
December 7, 2020
NCT06817382
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions